A novel antidepressant intervention for outpatient psychiatry

Dextromethorphan-bupropion shows promise for treatment-resistant depression (TRD) in a small sample of 52 patients, with 27 experiencing improvement within 2 weeks and 43 achieving remission after 2 months. The authors advocate for integrating novel antidepressants into TRD management guidelines, noting limitations including a medically underserved demographic and small sample size. They caution that results require further research.

Study at a glance

Abstract

This article explores the potential of the novel antidepressant dextromethorphan-bupropion in addressing treatment-resistant depression (TRD). Traditional approaches, including selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, alongside antipsychotic agents, often prove insufficient. Amid a global surge in TRD post-COVID-19, dextromethorphan-bupropion emerges as an effective treatment option for a subset of 52 patients. Results indicated 27 patients experienced improvement within 2 weeks and 43 achieved remission after 2 months of dextromethorphan-bupropion use. While acknowledging limitations, particularly in a medically under-served demographic, this article advocates for the integration of novel antidepressants into TRD management guidelines. Caution must be exercised given the small sample size; however, dextromethorphan-bupropion stands as a promising therapeutic cornerstone offering renewed hope to those navigating the challenging terrain of TRD and prompting broader discussions for future collaborative research.